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The ethical issues faced by clinicians have never been
more challenging than they are today. For surgeons,
awareness of ethical questions is perhaps even greater
as they are often involvedwith the introduction of new
techniques or technologies.
In a multicentre randomised control trial (RCT),
upon the completion of recruitment and before
publication of the results, there is always a period of
uncertainty over the best treatment. The ethical
dilemma that emerges for surgeons and their patients
is what treatment should be offered during this period
in view of the assumed equipoise between the
conventional and new treatment.
Two good examples are the EuropeanAsymptomatic
Carotid Surgery Trial (ACST)1,2 and the Endovascular
Aneurysm Repair (EVAR) Trial3 that will not publish
their results for at least 1 year after recruitment ends.Ethical Issues Related to RCTs
The ethical basis of a RCT is that it commences with a
honest null hypothesis, meaning that equipoise exists
between the arms of the trial.4,5 In trials with several
arms, equipoise must exist between all arms otherwise
the trial design should be modified to exclude the
inferior treatment.6 Randomised clinical trials should
be constructed such that patients are given access
either to the best standard therapy or to a new
treatment that is considered at least equivalent or
possibly superior to the standard treatment. Ifing author. Athanasios Giannoukas, Sheffield Vascular
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In addition, the clinician must inform suitable
patients about the pros and cons of both the new and
conventional treatment whilst making it clear that
there is still uncertainty over the best treatment until
the results are known.
The European Convention on Human Rights and
Biomedicine clearly states in article 16 that research
involving human subjects may only be undertaken if
there is no alternative of comparable effectiveness and
that the risks which may incurred by the participant
are not disproportionate to the potential benefits of the
research.8 It is also assumed that the researcher acts in
good faith with the interests of the profession and of
the public at heart.Clinical Practice while Awaiting the Results a RCT
For those centres not participating in a trial it seems
sensible to continue their established practice until the
publication of the results of the trial. However, for
those centres participating in a trial the period
between the end of recruitment and publication of
the results poses a dilemma with regard to treatment.
It remains important to remember two principles that
the clinician must respect i.e. the patient’s autonomy
and their right to be properly informed.
Autonomy is an important ethical issue. It can be
defined as the authority to make decisions in accord
with one’s own values, unrestrained by the values of
others who do not suffer the consequences of the
decision. Therefore, patients hold the authority to
make health-care decisions unrestrained by the values
of their clinicians, others in the healthcare industry, or
the rest of society.9 Documented informed consentEur J Vasc Endovasc Surg 28, 571–572 (2004)
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between clinicians and patients.10,11 Clinicians should
remain neutral when informing patients about their
treatment options. The pros and cons of each therapy
should be declared without bias.
This policy of openness increases patients’ satisfac-
tion, adherence to treatment, and reduces subsequent
complaints. Such a patient-centred approach is vital
for the physician–patient relationship.12 The pillars of
this relationship have been summarised as the six C’s:
choice, competence, communication, compassion,
continuity, and (no) conflict of interest.13
Because of the uncertainty over the best treatment
during this intermediate period, both alternative
treatments should continue where possible. The ability
to offer both treatments will depend upon mainten-
ance of equipoise and funding. Both the clinician and
patient need to remain in equipoise with regard to the
conventional and new treatment. This should present
less of a problem for the clinician, as the trial would
have been stopped prematurely by the data monitor-
ing committee if there had been a clear advantage of
one treatment over the other.
The EVAR and carotid stenting trials14 are those that
are currently ‘stealing the show’. Rumours about the
likely results of such trials are often available to
patients, especially via the Internet, which usually
favours the new treatment. Such new treatments are
also promoted by the commercial sector, which have a
vested financial interest. For instance, while some
reservations have been expressed from some research-
ers on the wide applicability of the results of the
SAPPHIRE study (Stenting and Angioplasty with
Protection in Patients at High Risk for Endarterect-
omy),15 it is anticipated that these results will be used
to grant a Premarket Approval (PMA) for the devices
employed in this FDA-approved trial. This ultimately
would result in easy availability of the devices and
liberalisation in the indications for carotid stenting.14
Therefore, it is the clinicians’ responsibility to ensure
that patients are not unduly biased by potentially
inaccurate information.
Continued funding of the new treatment is another
prerequisite. Many new treatments, such as EVAR,
may be more expensive than conventional treatment.
Therefore, funding agencies may be reluctant to
continue funding once recruitment has finished until
the results are known. This issue should be addressed
and incorporated into the trial design. A good example
is the EVAR trial where funding of the new treatment,
and randomisation, will continue after the end of the
trial until the results are published. This additional
data will not contribute to the initial results but will be
incorporated into subsequent analysis.Eur J Vasc Endovasc Surg Vol 28, December 2004Conclusion
Because of the uncertainty over the best treatment after
the end of recruitment in RCTs and until the
publication of the results, both the new and the
conventional treatments should be offered, based on
continued equipoise. This issue should be addressed
in the design of the RCTs as to ensure adequate
funding. Patient’s autonomy and their right to be
properly informed should always be respected. For
this reason, clinicians should ensure that patients
receive accurate information, not biased by the media
and non-professional sources.References
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